NewAmsterdam Pharma (NAMS) CEO sells 443,707 shares after option exercise

Rhea-AI Filing Summary

NewAmsterdam Pharma Co N.V. Chief Executive Officer Michael H. Davidson exercised options covering 443,707 ordinary shares and then sold 443,707 ordinary shares in an open-market transaction at $33.25 per share. Following these transactions, he directly owns 174,144 ordinary shares.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Davidson Michael H.

(Last) (First) (Middle)

C/O NEWAMSTERDAM PHARMA COMPANY N.V.

GOOIMEER 2-35

(Street)

NAARDEN P7 1411 DC

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
NewAmsterdam Pharma Co N.V. [ NAMS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

3. Date of Earliest Transaction (Month/Day/Year)
03/02/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares	03/02/2026		M		443,707	A	(1)	617,851	D
Ordinary Shares	03/02/2026		S		443,707	D	$33.25	174,144	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Option (right to buy)	(1)	03/02/2026		M			443,707	(2)	07/06/2031	Ordinary Shares	443,707	$0	239,267	D

Explanation of Responses:

1. The exercise price of the option is EUR 1.16392.

2. The option was granted on November 22, 2022 to replace options originally granted on July 6, 2021 which was cancelled in connection with the consummation of NewAmsterdam Pharma Company N.V.'s business combination with Frazier Lifesciences Acquisition Corporation. 25% of the shares underlying the options vested on August 1, 2021, the one-year anniversary of vesting start date, with the remaining shares vesting in equal monthly installments thereafter for three years, subject to the Reporting Person's continued service through each such date.

	/s/ Michael H. Davidson	03/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did NewAmsterdam Pharma (NAMS) report for Michael H. Davidson?

NewAmsterdam Pharma reported that CEO Michael H. Davidson exercised options for 443,707 ordinary shares and sold 443,707 ordinary shares in an open-market transaction. After these transactions, he directly holds 174,144 ordinary shares in the company.

How many NewAmsterdam Pharma (NAMS) shares did the CEO sell and at what price?

The CEO sold 443,707 ordinary shares of NewAmsterdam Pharma at a price of $33.25 per share. This sale followed his exercise of options for the same number of shares on the same date, according to the Form 4 disclosure.

Did the NewAmsterdam Pharma (NAMS) CEO acquire additional shares through option exercise?

Yes. Michael H. Davidson exercised options described as a right to buy 443,707 ordinary shares. The Form 4 notes this as an exercise or conversion of a derivative security, followed by an open-market sale of an equal number of ordinary shares.

How many NewAmsterdam Pharma (NAMS) shares does the CEO hold after these transactions?

After the reported transactions, Michael H. Davidson directly owns 174,144 ordinary shares of NewAmsterdam Pharma. This figure reflects his holdings following the option exercise and subsequent sale of 443,707 ordinary shares reported in the Form 4 filing.

What does transaction code M mean in the NewAmsterdam Pharma (NAMS) Form 4?

Transaction code M in the filing indicates an exercise or conversion of a derivative security, such as a stock option. In this case, it reflects the conversion of options into 443,707 ordinary shares before those shares were sold in the open market.

Were the NewAmsterdam Pharma (NAMS) CEO’s transactions direct or through an entity?

The Form 4 characterizes the CEO’s holdings and transactions as direct, using the direct ownership code. No footnotes indicate that the shares are held by a separate trust, partnership, or other entity on his behalf in this disclosure.